Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $28.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $0.00.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $1.00K.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $3.00K.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $31.00K, a 93.56% decline from fiscal 2022.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $481.00K, a 92.24% decline from fiscal 2021.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $6.20M, a 181.82% increase from fiscal 2020.
- Vaxart, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $2.20M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00K 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $0.00 S-1 · filed 2026-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-05-08 | $1.00K derived: sum of 3 quarters · filed 2026-05-08 | $4.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $1.00K derived: sum of 2 quarters · filed 2026-05-08 | $4.00K derived: sum of 3 quarters · filed 2026-05-08 | $7.00K S-1 · filed 2026-05-08 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.00K derived: sum of 2 quarters · filed 2024-11-13 | $7.00K 10-Q · filed 2024-11-13 | $7.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.00K 10-Q · filed 2024-08-08 | $6.00K derived: sum of 3 quarters · filed 2025-03-20 | $6.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $3.00K 10-Q · filed 2024-05-13 | $3.00K derived: sum of 2 quarters · filed 2025-03-20 | $3.00K derived: sum of 3 quarters · filed 2025-03-20 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $31.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $31.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $31.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $256.00K derived: sum of 2 quarters · filed 2024-03-14 | $380.00K derived: sum of 3 quarters · filed 2024-03-14 | $481.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $373.00K derived: sum of 2 quarters · filed 2023-11-02 | $474.00K 10-Q · filed 2023-11-02 | $2.07M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $225.00K 10-Q · filed 2023-08-03 | $1.82M derived: sum of 3 quarters · filed 2023-08-03 | $3.23M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $101.00K 10-Q · filed 2022-05-09 | $1.70M derived: sum of 2 quarters · filed 2023-03-15 | $3.10M derived: sum of 3 quarters · filed 2023-03-15 | $5.20M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $3.00M derived: sum of 2 quarters · filed 2023-03-15 | $5.10M derived: sum of 3 quarters · filed 2023-03-15 | $6.20M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $3.50M derived: sum of 2 quarters · filed 2022-11-09 | $4.60M 10-Q · filed 2022-11-09 | $5.20M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.20M 10-Q · filed 2022-08-08 | $3.80M derived: sum of 3 quarters · filed 2022-08-08 | $4.88M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.10M 10-Q · filed 2022-05-09 | $1.70M derived: sum of 2 quarters · filed 2022-05-09 | $2.78M derived: sum of 3 quarters · filed 2022-05-09 | $3.27M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.68M derived: sum of 2 quarters · filed 2022-02-24 | $2.17M derived: sum of 3 quarters · filed 2022-02-24 | $2.20M 10-K · filed 2022-02-24 |
| 2020-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.57M derived: sum of 2 quarters · filed 2021-11-04 | $1.60M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $524.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $25.00K 10-Q · filed 2021-05-06 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 | |||
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | $0.00 10-K · filed 2017-09-01 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-08 | |||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-08 | |||
| 2016-06-30 | $0.00 10-K · filed 2017-09-01 | |||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $0.00 10-K · filed 2016-09-13 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2015-05-08 | $0.00 derived: sum of 3 quarters · filed 2015-05-08 | $0.00 derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | $0.00 10-Q · filed 2015-02-06 | $0.00 derived: sum of 2 quarters · filed 2015-02-06 | $0.00 derived: sum of 3 quarters · filed 2015-02-06 | $0.00 derived: sum of 4 quarters · filed 2015-02-06 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $0.00 derived: sum of 3 quarters · filed 2014-11-07 | |
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-30 | $0.00 derived: sum of 2 quarters · filed 2014-09-30 | $0.00 10-K · filed 2014-09-30 | |
| 2014-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-12 | $0.00 10-Q · filed 2014-05-12 | ||
| 2013-12-31 | $0.00 10-Q · filed 2014-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |